J Liver Cancer.  2021 Mar;21(1):12-24. 10.17998/jlc.21.1.12.

Update on Pathologic and Radiologic Diagnosis of Combined Hepatocellular-Cholangiocarcinoma

• Rhee H
• Park JH
• Park YN

• KMID: 2514231
• DOI: http://doi.org/10.17998/jlc.21.1.12

Abstract

Combined hepatocellular-cholangiocarcinoma (cHCC-CCA) is a malignant primary liver carcinoma characterized by the unequivocal presence of both hepatocytic and cholangiocytic differentiation within the same tumor. Recent research has highlighted that cHCC-CCAs are more heterogeneous than previously expected. In the updated consensus terminology and WHO 2019 classification, “classical type” and “subtypes with stem-cell features” of the WHO 2010 classification are no longer recommended. Instead, it is recommended that the presence and percentages of various histopathologic components and stem-cell features be mentioned in the pathologic report. The new terminology and classification enable the exchange of clearer and more objective information about cHCC-CCAs, facilitating multi-center and multinational research. However, there are limitations to the diagnosis of cHCC-CCA by imaging and biopsy. cHCC-CCAs showing typical imaging findings of HCC could be misdiagnosed as HCC and subjected to inappropriate treatment, if other clinical findings are not sufficiently considered. cHCC-CCAs showing at least one of the CCA-like imaging features or unusual clinical features should be subjected to biopsy. There may be a sampling error for the biopsy diagnosis of cHCC-CCA. An optimized diagnostic algorithm integrating clinical, radiological, and histopathologic information of biopsy is required to resolve these diagnostic pitfalls.

Keyword

Liver neoplasm; Diagnosis; Stem cell; Magnetic resonance imaging; Biopsy

Figure

• 

  Figure 1 A 57-year-old male with combined hepatocellular-cholangiocarcinoma (cHCC-CCA) in the background liver of hepatitis B-virus and alcohol related chronic hepatitis. A 3.4-cm infiltrative mass lesion in the liver segment 7 shows low-signal intensity in precontrast T1-weighted image (A), peripheral enhancement in the arterial phase (B), absence of washout in portal phase (C) and 2-minute delay phase (D), decreased hepatobiliary uptake in hepatobiliary phase (E), and high-signal intensity in T2-weighted image (F) of gadoxetate-enhanced magnetic resonance imaging. It is categorized as Liver Imaging Reporting and Data System M based on targetoid appearance. On pathologic examination (G–I), the tumor shows cholangiocarcinoma (CCA) component in whitish and fibrotic area of gross specimen and hepatocellular carcinoma (HCC) component in more yellowish area of resected specimen, and there are transitional differentiation zones between them (G, gross feature of resected specimen; H, scanning view of hematoxylin-eosin stain; I, map of histological components). HCC and CCA areas are not distinguishable in magnetic resonance imaging.

• 

  Figure 2 A 58-year-old male showing combined hepatocellular-cholangiocarcinoma (cHCC-CCA) with cholangiolocellular (CLC) and intermediate-cell carcinoma components, developed in cirrhosis of unknown etiology. A 3.2-cm lobulated mass lesion in the liver segment 4 shows low-signal intensity in precontrast T1-weighted image (A), peripheral enhancement in the arterial phase (B), absence of washout in portal phase (C) and delayed central enhancement in hepatobiliary phase (D) of gadoxetate-enhanced magnetic resonance imaging (MRI). The lesion also shows nodule-in-nodule appearance: the inner nodule exhibited hypervascularity in arterial phase, absence of washout in portal phase, and low-signal intensity in T2-weighted image (E). As the lesion shows peripheral arterial enhancement and delayed central enhancement, it is categorized as Liver Imaging Reporting and Data System M. On pathologic examination (F–L), the tumor shows complex mixture of hepatocellular carcinoma (HCC) (I), intermediate-cell carcinoma (J), CLC (K), and cholangiocarcinoma (CCA) (L) components. On MRI, the CCA component, corresponding the inner nodule, was more hypervascular than other components including HCC ([F] gross feature of resected specimen; [G] scanning view of hematoxylin-eosin [H–E] stain; [H] map of histological components; [I–L] H–E stain, original magnification, ×100).

• 

  Figure 3 A 50-year-old female showing combined hepatocellular-cholangiocarcinoma (cHCC-CCA), developed in B viral cirrhosis. A 1.7-cm tumor in the liver segment 2 shows low-signal intensity on precontrast T1-weighted image (A), non-peripheral enhancement in the arterial phase (B), washout and enhancing capsule on portal phase (C) and 2-minutes delay phase (D) of gadoterate meglumine-enhanced magnetic resonance imaging (white arrows). The lesion also shows high signal intensity in T2-weighted image (E) and diffusion-weighted image (F, b=800). Since the lesion exhibits three major features of Liver Imaging and Reporting and Data System, it is categorized as HCC (LR-5). On pathologic examination, the tumor is composed of two histologic components (G–L), showing large area of HCC (J) and small area of CCA (K) on hematoxylin-eosin (H–E) staining. Alcian-blue staining shows mucin, stained as blue color, at CCA (L, red arrows) ([G] gross feature of resected specimen; [H] scanning view of H–E stain; [I] map of histological component; [J, K] H–E stain, original magnification, ×100; [L] scanning view of Alcian-blue stain).

• 

  Figure 4 A 67-year-old male with combined hepatocellular-cholangiocarcinoma (cHCC-CCA), developed in C viral cirrhosis with matched biopsied and resected specimen. The gadoxetate-enhanced magnetic resonance imaging shows approximately 2.4 cm mass lesion with low-signal intensity in precontrast T1-weighted image (A), peripheral enhancement in the arterial phase (B), absence of washout in portal phase (C) and decreased hepatobiliary uptake in hepatobiliary phase (D), high signal intensity in T2-weighted image (E), and targetoid restriction in diffusion-weighted image (F, b=800). The patient has past history of distal common bile duct cancer (26 years ago), and recently diagnosed squamous cell carcinoma of oral cavity. To determine whether the lesion is metastasis, percutaneous liver biopsy was performed. The biopsy specimen shows adenocarcinoma without other component (G, H). The patient underwent hepatic resection and the tumor reveals cHCC-CCA (I, J). There is large area of cholangiocarcinoma (approximately 90%) and small area of hepatocellular carcinoma (approximately 10%) with transitional differentiation zones between them ([G] hematoxylin-eosin stain [H–E], original magnification, ×100; [H, I] scanning view of H–E stain; [J] H–E stain, original magnification, ×40).

Reference

1. Brunt E, Aishima S, Clavien PA, Fowler K, Goodman Z, Gores G, et al. cHCC-CCA: Consensus terminology for primary liver carcinomas with both hepatocytic and cholangiocytic differentation. Hepatology. 2018; 68:113–126.

2. Edmondson HA, Steiner PE. Primary carcinoma of the liver: a study of 100 cases among 48,900 necropsies. Cancer. 1954; 7:462–503.

3. Wachtel MS, Zhang Y, Xu T, Chiriva-Internati M, Frezza EE. Combined hepatocellular cholangiocarcinomas; analysis of a large database. Clin Med Pathol. 2008; 1:43–47.

4. Sempoux C, Kakar S, Kondo F, Schirmacher P. Combined hepatocellular-cholangiocarcinoma and undifferentiated primary liver carcinoma. World Health Organization. WHO Classification of Tumours. 1:5th ed. 2019. p. 260–262.

5. Gera S, Ettel M, Acosta-Gonzalez G, Xu R. Clinical features, histology, and histogenesis of combined hepatocellular-cholangiocarcinoma. World J Hepatol. 2017; 9:300–309.

6. Akiba J, Nakashima O, Hattori S, Tanikawa K, Takenaka M, Nakayama M, et al. Clinicopathologic analysis of combined hepatocellular-cholangiocarcinoma according to the latest WHO classification. Am J Surg Pathol. 2013; 37:496–505.

7. Sasaki M, Sato H, Kakuda Y, Sato Y, Choi JH, Nakanuma Y. Clinicopathological significance of ‘subtypes with stem-cell feature’ in combined hepatocellular-cholangiocarcinoma. Liver Int. 2015; 35:1024–1035.

8. Sempoux C, Paradis V, Saxena R. Variant differentiation patterns in primary liver carcinoma. Semin Diagn Pathol. 2017; 34:176–182.

9. Komuta M, Spee B, Vander Borght S, De Vos R, Verslype C, Aerts R, et al. Clinicopathological study on cholangiolocellular carcinoma suggesting hepatic progenitor cell origin. Hepatology. 2008; 47:1544–1556.

10. Komuta M, Govaere O, Vandecaveye V, Akiba J, Van Steenbergen W, Verslype C, et al. Histological diversity in cholangiocellular carcinoma reflects the different cholangiocyte phenotypes. Hepatology. 2012; 55:1876–1888.

11. Moeini A, Sia D, Zhang Z, Camprecios G, Stueck A, Dong H, et al. Mixed hepatocellular cholangiocarcinoma tumors: cholangiolocellular carcinoma is a distinct molecular entity. J Hepatol. 2017; 66:952–961.

12. Maeno S, Kondo F, Sano K, Takada T, Asano T. Morphometric and immunohistochemical study of cholangiolocellular carcinoma: comparison with non-neoplastic cholangiole, interlobular duct and septal duct. J Hepatobiliary Pancreat Sci. 2012; 19:289–296.

13. Yeh MM. Pathology of combined hepatocellular-cholangiocarcinoma. J Gastroenterol Hepatol. 2010; 25:1485–1492.

14. Coulouarn C, Cavard C, Rubbia-Brandt L, Audebourg A, Dumont F, Jacques S, et al. Combined hepatocellular-cholangiocarcinomas exhibit progenitor features and activation of Wnt and TGFbeta signaling pathways. Carcinogenesis. 2012; 33:1791–1796.

15. Holczbauer Á, Factor VM, Andersen JB, Marquardt JU, Kleiner DE, Raggi C, et al. Modeling pathogenesis of primary liver cancer in lineage-specific mouse cell types. Gastroenterology. 2013; 145:221–231.

16. Li L, Qian M, Chen IH, Finkelstein D, Onar-Thomas A, Johnson M, et al. Acquisition of cholangiocarcinoma traits during advanced hepatocellular carcinoma development in mice. Am J Pathol. 2018; 188:656–671.

17. Zen C, Zen Y, Mitry RR, Corbeil D, Karbanová J, O’Grady J, et al. Mixed phenotype hepatocellular carcinoma after transarterial chemoembolization and liver transplantation. Liver Transpl. 2011; 17:943–954.

18. Fujii H, Zhu XG, Matsumoto T, Inagaki M, Tokusashi Y, Miyokawa N, et al. Genetic classification of combined hepatocellular-cholangiocarcinoma. Hum Pathol. 2000; 31:1011–1017.

19. Wang A, Wu L, Lin J, Han L, Bian J, Wu Y, et al. Whole-exome sequencing reveals the origin and evolution of hepato-cholangiocarcinoma. Nat Commun. 2018; 9:894.

20. Joseph NM, Tsokos CG, Umetsu SE, Shain AH, Kelley RK, Onodera C, et al. Genomic profiling of combined hepatocellular-cholangiocarcinoma reveals similar genetics to hepatocellular carcinoma. J Pathol. 2019; 248:164–178.

21. Cazals-Hatem D, Rebouissou S, Bioulac-Sage P, Bluteau O, Blanché H, Franco D, et al. Clinical and molecular analysis of combined hepatocellular-cholangiocarcinomas. J Hepatol. 2004; 41:292–298.

22. Fujimoto A, Furuta M, Shiraishi Y, Gotoh K, Kawakami Y, Arihiro K, et al. Whole-genome mutational landscape of liver cancers displaying biliary phenotype reveals hepatitis impact and molecular diversity. Nat Commun. 2015; 6:6120.

23. Liu ZH, Lian BF, Dong QZ, Sun H, Wei JW, Sheng YY, et al. Whole-exome mutational and transcriptional landscapes of combined hepatocellular cholangiocarcinoma and intrahepatic cholangiocarcinoma reveal molecular diversity. Biochim Biophys Acta Mol Basis Dis. 2018; 1864(6 Pt B):2360–2368.

24. Park SH, Lee SS, Yu E, Kang HJ, Park Y, Kim SY, et al. Combined hepatocellular-cholangiocarcinoma: gadoxetic acid-enhanced MRI findings correlated with pathologic features and prognosis. J Magn Reson Imaging. 2017; 46:267–280.

25. Kim JH, Yoon HK, Ko GY, Gwon DI, Jang CS, Song HY, et al. Non-resectable combined hepatocellular carcinoma and cholangiocarcinoma: analysis of the response and prognostic factors after transcatheter arterial chemoembolization. Radiology. 2010; 255:270–277.

26. Aoki K, Takayasu K, Kawano T, Muramatsu Y, Moriyama N, Wakao F, et al. Combined hepatocellular carcinoma and cholangiocarcinoma: clinical features and computed tomographic findings. Hepatology. 1993; 18:1090–1095.

27. Chantajitr S, Wilasrusmee C, Lertsitichai P, Phromsopha N. Combined hepatocellular and cholangiocarcinoma: clinical features and prognostic study in a Thai population. J Hepatobiliary Pancreat Surg. 2006; 13:537–542.

28. Ramai D, Ofosu A, Lai JK, Reddy M, Adler DG. Combined hepatocellular cholangiocarcinoma: a population-based retrospective study. Am J Gastroenterol. 2019; 114:1496–1501.

29. Yano Y, Yamamoto J, Kosuge T, Sakamoto Y, Yamasaki S, Shimada K, et al. Combined hepatocellular and cholangiocarcinoma: a clinicopathologic study of 26 resected cases. Jpn J Clin Oncol. 2003; 33:283–287.

30. Koh KC, Lee H, Choi MS, Lee JH, Paik SW, Yoo BC, et al. Clinicopathologic features and prognosis of combined hepatocellular cholangiocarcinoma. Am J Surg. 2005; 189:120–125.

31. Liu CL, Fan ST, Lo CM, Ng IO, Lam CM, Poon RT, et al. Hepatic resection for combined hepatocellular and cholangiocarcinoma. Arch Surg. 2003; 138:86–90.

32. Jarnagin WR, Weber S, Tickoo SK, Koea JB, Obiekwe S, Fong Y, et al. Combined hepatocellular and cholangiocarcinoma: demographic, clinical, and prognostic factors. Cancer. 2002; 94:2040–2046.

33. Palmer WC, Patel T. Are common factors involved in the pathogenesis of primary liver cancers? A meta-analysis of risk factors for intrahepatic cholangiocarcinoma. J Hepatol. 2012; 57:69–76.

34. Maeda T, Adachi E, Kajiyama K, Sugimachi K, Tsuneyoshi M. Combined hepatocellular and cholangiocarcinoma: proposed criteria according to cytokeratin expression and analysis of clinicopathologic features. Hum Pathol. 1995; 26:956–964.

35. Tang D, Nagano H, Nakamura M, Wada H, Marubashi S, Miyamoto A, et al. Clinical and pathological features of Allen’s type C classification of resected combined hepatocellular and cholangiocarcinoma: a comparative study with hepatocellular carcinoma and cholangiocellular carcinoma. J Gastrointest Surg. 2006; 10:987–998.

36. Lee WS, Lee KW, Heo JS, Kim SJ, Choi SH, Kim YI, et al. Comparison of combined hepatocellular and cholangiocarcinoma with hepatocellular carcinoma and intrahepatic cholangiocarcinoma. Surg Today. 2006; 36:892–897.

37. Kassahun WT, Hauss J. Management of combined hepatocellular and cholangiocarcinoma. Int J Clin Pract. 2008; 62:1271–1278.

38. Wells ML, Venkatesh SK, Chandan VS, Fidler JL, Fletcher JG, Johnson GB, et al. Biphenotypic hepatic tumors: imaging findings and review of literature. Abdom Imaging. 2015; 40:2293–2305.

39. Kim TH, Kim SY, Tang A, Lee JM. Comparison of international guidelines for noninvasive diagnosis of hepatocellular carcinoma: 2018 update. Clin Mol Hepatol. 2019; 25:245–263.

40. American College of Radiology. Liver imaging reporting and data system version 2018 [Internet]. Reston (USA): American College of Radiology;[cited 2020 Jun 30]. Available from: https://www.acr.org/Clinical-Resources/Reporting-and-Data-Systems/LI-RADS/CT-MRI-LI-RADS-v2018.

41. Marrero JA, Kulik LM, Sirlin CB, Zhu AX, Finn RS, Abecassis MM, et al. Diagnosis, staging, and management of hepatocellular carcinoma: 2018 practice guidance by the American Association for the Study of Liver Diseases. Hepatology. 2018; 68:723–750.

42. Fowler KJ, Sheybani A, Parker RA 3rd, Doherty S, Brunt EM, Chapman WC, et al. Combined hepatocellular and cholangiocarcinoma (biphenotypic) tumors: imaging features and diagnostic accuracy of contrast-enhanced CT and MRI. AJR Am J Roentgenol. 2013; 201:332–339.

43. de Campos RO, Semelka RC, Azevedo RM, Ramalho M, Heredia V, Armao DM, et al. Combined hepatocellular carcinoma-cholangiocarcinoma: report of MR appearance in eleven patients. J Magn Reson Imaging. 2012; 36:1139–1147.

44. Hwang J, Kim YK, Park MJ, Lee MH, Kim SH, Lee WJ, et al. Differentiating combined hepatocellular and cholangiocarcinoma from mass-forming intrahepatic cholangiocarcinoma using gadoxetic acid-enhanced MRI. J Magn Reson Imaging. 2012; 36:881–889.

45. Potretzke TA, Tan BR, Doyle MB, Brunt EM, Heiken JP, Fowler KJ. Imaging features of biphenotypic primary liver carcinoma (hepatocholangiocarcinoma) and the potential to mimic hepatocellular carcinoma: LI-RADS analysis of CT and MRI features in 61 cases. AJR Am J Roentgenol. 2016; 207:25–31.

46. Sammon J, Fischer S, Menezes R, Hosseini-Nik H, Lewis S, Taouli B, et al. MRI features of combined hepatocellular-cholangiocarcinoma versus mass forming intrahepatic cholangiocarcinoma. Cancer Imaging. 2018; 18:8.

47. Kim SS, Lee S, Choi JY, Lim JS, Park MS, Kim MJ. Diagnostic performance of the LR-M criteria and spectrum of LI-RADS imaging features among primary hepatic carcinomas. Abdom Radiol (NY). 2020; 45:3743–3754.

48. Jeon SK, Joo I, Lee DH, Lee SM, Kang HJ, Lee KB, et al. Combined hepatocellular cholangiocarcinoma: LI-RADS v2017 categorisation for differential diagnosis and prognostication on gadoxetic acid-enhanced MR imaging. Eur Radiol. 2019; 29:373–382.

49. Lee HS, Kim MJ, An C. How to utilize LR-M features of the LI-RADS to improve the diagnosis of combined hepatocellular-cholangiocarcinoma on gadoxetate-enhanced MRI? Eur Radiol. 2019; 29:2408–2416.

50. Mao Y, Xu S, Hu W, Huang J, Wang J, Zhang R, et al. Imaging features predict prognosis of patients with combined hepatocellular-cholangiocarcinoma. Clin Radiol. 2017; 72:129–135.

51. An C, Park S, Chung YE, Kim DY, Kim SS, Kim MJ, et al. Curative resection of single primary hepatic malignancy: liver imaging reporting and data system category LR-M portends a worse prognosis. AJR Am J Roentgenol. 2017; 209:576–583.

52. Gigante E, Ronot M, Bertin C, Ciolina M, Bouattour M, Dondero F, et al. Combining imaging and tumour biopsy improves the diagnosis of combined hepatocellular-cholangiocarcinoma. Liver Int. 2019; 39:2386–2396.

53. Nahm JH, Rhee H, Kim H, Yoo JE, Lee JS, Jeon Y, et al. Increased expression of stemness markers and altered tumor stroma in hepatocellular carcinoma under TACE-induced hypoxia: a biopsy and resection matched study. Oncotarget. 2017; 8:99359–99371.